The BCHE Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated by disrupting the BCHE gene in the HAP1 cell line. This product offers a heterogeneous pool of cells carrying loss-of-function alleles across the BCHE locus, enabling robust functional genomics studies without clonal selection biases. The polyclonal format preserves genetic diversity while ensuring targeted disruption of butyrylcholinesterase, making it an ideal model for high-throughput genetic screens and pooled analyses.
HAP1 is a near-haploid, fibroblast-like human cell line originally derived from the KBM-7 chronic myeloid leukemia line, which harbors the BCR-ABL fusion. Its haploid karyotype minimizes allelic complexity, facilitating precise gene editing and straightforward interpretation of knockout phenotypes. HAP1 cells are widely employed in functional genomics, drug target discovery, and CRISPR-based interaction studies, owing to their stable growth and ease of manipulation.
BCHE encodes butyrylcholinesterase, a serine hydrolase that hydrolyzes choline esters, including the neurotransmitter acetylcholine and exogenous compounds such as succinylcholine and organophosphates. This enzymatic activity modulates cholinergic signaling and xenobiotic metabolism, with downstream effects on acetylcholine and choline levels that ultimately influence carboxylic acid metabolite pools. BCHE expression is transcriptionally regulated by C/EBP transcription factors and glucocorticoid receptor signaling. Within the cholinergic synapse, butyrylcholinesterase functions alongside acetylcholinesterase (AChE) and choline acetyltransferase to terminate neurotransmission, and it serves as a key target for cholinesterase inhibitors. Consequently, the enzyme directly interacts with substrates and inhibitors, shaping cellular responses to neurotoxins and therapeutic drugs.
Disruption of BCHE in HAP1 cells impairs acetylcholine degradation and other choline ester hydrolysis reactions, leading to altered cholinergic signaling dynamics and modified sensitivity to cholinesterase-targeting compounds. This knockout model recapitulates key aspects of butyrylcholinesterase deficiency and provides a defined genetic background for dissecting the enzyme??s roles in drug metabolism, neurotoxicity, and cholinergic physiology. Because HAP1 retains leukemia-derived signaling networks including BCR-ABL, the BCHE knockout can also be employed to investigate interactions between butyrylcholinesterase activity and oncogenic pathways.
The BCHE Knockout HAP1 Polyclonal Cells are suited for diverse research applications, including xenobiotic metabolism studies, neurotoxicity screening, and functional characterization of cholinesterase inhibitors. Typical assays involve spectrophotometric or fluorometric cholinesterase activity measurements to confirm loss of butyrylcholinesterase function, western blotting and RT?qPCR to assess BCHE protein and transcript levels, and ELISA-based quantification of cholinergic biomarkers. Furthermore, these cells enable dose?Cresponse profiling of organophosphates and other cholinesterase-targeting compounds, facilitating drug sensitivity and resistance research. For additional information, please contact Ascent Research.
